GRCE Financials

Income Statement
MetricQ2 2027Q1 2027Q4 2026Q3 2026Q2 2026
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.3M
-85.6%
15.9M
+428.8%
3.0M
+22.9%
2.4M
-3.2%
2.5M
R&D
885.0K
+27.0%
697.0K
+66.0%
420.0K
-9.1%
462.0K
-18.7%
568.0K
SG&A
1.4M
-16.6%
1.7M
-34.9%
2.6M
+30.3%
2.0M
+1.3%
2.0M
Operating Income
-2292000
+85.6%
-15917000
-428.8%
-3010000
-22.9%
-2449000
+3.2%
-2529000
EBITDA
-2291000
+3.8%
-2382000
+20.8%
-3008000
-23.0%
-2446000
+3.3%
-2529000
Net Income
-2131000
+86.5%
-15790000
-1240.4%
-1178000
+49.1%
-2315000
-146.8%
-938000
EPS (Basic)
$-0.11
+87.9%
$-0.91
-1200.0%
$-0.07
+50.0%
$-0.14
-133.3%
$-0.06
EPS (Diluted)
$-0.11
+87.9%
$-0.91
-1200.0%
$-0.07
+50.0%
$-0.14
-133.3%
$-0.06
Shares (Diluted)
20.1M
+16.5%
17.3M
+0.1%
17.3M
+1.9%
16.9M
+6.3%
15.9M
Grace Therapeutics (GRCE) — Financials